Anaptys Positive Rosnilimab Data Updated Through 6 Months in Robust Phase 2b Trial in RA

AnaptysBio (ANAB) announced positive 6-month data for rosnilimab in Phase 2b trial for moderate-to-severe rheumatoid arthritis. The drug demonstrated JAK-like efficacy with monthly dosing, achieving significant improvements in disease activity measures. The 424-patient trial showed 69% of patients achieved low disease activity (LDA) across all doses at Week 14, with responses lasting at least 2 months after treatment. The drug showed favorable safety with no treatment-related serious adverse events. In b/tsDMARD-naive patients, LDA rates reached up to 72% at Week 28, while b/tsDMARD-experienced patients showed up to 56% LDA. The drug demonstrated ~50% reduction in CRP levels and ~90% reduction in PD-1high T cells, indicating strong anti-inflammatory effects. Rosnilimab targets the ~$20 billion U.S. RA market, with potential for extended dosing intervals during maintenance treatment.

https://www.stocktitan.net/news/ANAB/anaptys-announces-positive-rosnilimab-data-updated-through-six-i8xizwxvx1f8.html